Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.

E Cristiano1

  • 1Departamento de Neurología, Hospital Italiano de Buenos Aires, Argentina.

International Journal of Clinical Practice. Supplement
|February 5, 2003
PubMed
Summary

For multiple sclerosis (MS) management, higher doses and frequent administration of interferon (IFN) beta are more effective. A study found IFN beta-1a at 44 mcg three times weekly is superior to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flooded with potential: urban drainage science as seen by early-career researchers.

Water science and technology : a journal of the International Association on Water Pollution Research·2025
Same author

[Core data set for real world data in multiple sclerosis: customization for latin america from a global task force recommendation].

Revista de neurologia·2024
Same author

Trabecular bone score in people with cystic fibrosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

[Argentinean consensus guidelines on the identification and clinical care of secondary progressive multiple sclerosis].

Revista de neurologia·2020
Same author

Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina.

Multiple sclerosis and related disorders·2020
Same author

Disease activity impacts disability progression in primary progressive multiple sclerosis.

Multiple sclerosis and related disorders·2019

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Therapeutic effectiveness is paramount in chronic disease management.
  • Neurologists prioritize treatment efficacy when selecting therapies for multiple sclerosis (MS).
  • Interferon (IFN) beta is generally considered more efficacious than glatiramer acetate for MS.

Purpose of the Study:

  • To evaluate the comparative efficacy of different interferon beta (IFN beta) formulations and administration regimens for multiple sclerosis (MS).
  • To determine optimal dosing and frequency for maximizing therapeutic effectiveness in MS management.

Main Methods:

  • A Class I comparative trial was conducted.
  • Two commercial preparations of interferon beta-1a (IFN beta-1a) were evaluated.
  • Efficacy was assessed for subcutaneous administration of IFN beta-1a (44 mcg three times weekly) versus intramuscular administration of IFN beta-1 (30 mcg once weekly).

Related Experiment Videos

Main Results:

  • Preliminary results indicated significantly greater efficacy for IFN beta-1a (44 mcg) administered subcutaneously three times weekly.
  • This regimen demonstrated superior effectiveness compared to IFN beta-1 (30 mcg) administered intramuscularly once weekly.
  • High-dose, frequent administration of IFN beta is supported for maximal therapeutic effects.

Conclusions:

  • Interferon beta-1a (IFN beta-1a) at 44 mcg administered subcutaneously three times weekly provides maximal efficacy for patients with relapsing forms of MS.
  • Frequent administration and higher doses of IFN beta are recommended for optimal management of multiple sclerosis.
  • Treatment effectiveness remains the primary driver for therapeutic choices in MS.